Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bellicum Pharma Comm (BLCM)

Bellicum Pharma Comm (BLCM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,736
  • Shares Outstanding, K 5,060
  • Annual Sales, $ 7,140 K
  • Annual Income, $ -112,480 K
  • 60-Month Beta 2.16
  • Price/Sales 2.08
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BLCM with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -1.05
  • Number of Estimates 1
  • High Estimate -1.05
  • Low Estimate -1.05
  • Prior Year -2.94
  • Growth Rate Est. (year over year) +64.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.74 +13.50%
on 11/17/20
6.65 -53.23%
on 10/29/20
-3.09 (-49.84%)
since 10/23/20
3-Month
2.74 +13.50%
on 11/17/20
8.19 -62.03%
on 09/15/20
-3.06 (-49.59%)
since 08/25/20
52-Week
2.74 +13.50%
on 11/17/20
27.90 -88.85%
on 01/17/20
-5.65 (-64.51%)
since 11/25/19

Most Recent Stories

More News
Cronos Group (CRON) Catches Eye: Stock Jumps 9.3%

Cronos Group (CRON) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

BLCM : 3.11 (+6.14%)
Bellicum Pharmaceuticals (BLCM) Upgraded to Buy: Here's What You Should Know

Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BLCM : 3.11 (+6.14%)
Rising P/E: An Ignored Trick to Pick 5 Winning Stocks

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

CAH : 53.77 (-0.37%)
FNF : 36.99 (-0.19%)
QLYS : 91.88 (+0.66%)
GLUU : 9.50 (-0.52%)
BLCM : 3.11 (+6.14%)
Bellicum Pharmac Rises 8.65% on Heavy Volume: Watch For Potential Pullback

Bellicum Pharmac (NASDAQ:BLCM) traded in a range yesterday that spanned from a low of $2.92 to a high of $3.14. Yesterday, the shares gained 8.7%, which took the trading range above the 3-day high of...

BLCM : 3.11 (+6.14%)
Bellicum Reports Third Quarter 2020 Financial Results and Provides Operational Update

Strategic focus on clinical GoCAR-T programs with plans to initiate Phase 1/2 enrollment of BPX-601 in mCRPC and BPX-603 in HER2+ solid tumors by end of year

BLCM : 3.11 (+6.14%)
Bellicum Pharmaceuticals Announces Closing of $25.0 Million Underwritten Offering

Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the closing of its underwritten offering of 1,040,000 shares...

BLCM : 3.11 (+6.14%)
Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market

Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of an underwritten offering priced at-the-market...

BLCM : 3.11 (+6.14%)
Bellicum Announces Interim BPX-601 Data and Corporate Restructuring

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced interim data from its BPX-601 dose-escalation clinical trial...

BLCM : 3.11 (+6.14%)
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to one new employee consisting of...

BLCM : 3.11 (+6.14%)
Bellicum to Participate in Two Upcoming Virtual Conferences

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that management will participate in two upcoming virtual conferences....

BLCM : 3.11 (+6.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company's lead clinical product...

See More

Key Turning Points

2nd Resistance Point 3.34
1st Resistance Point 3.22
Last Price 3.11
1st Support Level 2.95
2nd Support Level 2.80

See More

52-Week High 27.90
Fibonacci 61.8% 18.29
Fibonacci 50% 15.32
Fibonacci 38.2% 12.35
Last Price 3.11
52-Week Low 2.74

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar